Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
暂无分享，去创建一个
F. Meric-Bernstam | B. Melichar | K. Jung | Susana Banerjee | S. Siena | D. Oh | I. Lugowska | A. Oaknin | D. Stroyakovskiy | Jung-Yun Lee | A. Manzano | A. González Martín | V. Makker | S. Puvvada | L. Manso | Yan Ma | Susana N. Banerjee | C. Anoka